158 related articles for article (PubMed ID: 29768630)
21. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma.
Fujita A; Hyodoh H; Kawamura Y; Kanegae K; Furuse M; Kanazawa K
Clin Nucl Med; 2000 Jun; 25(6):440-2. PubMed ID: 10836692
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.
Casey RT; Warren AY; Martin JE; Challis BG; Rattenberry E; Whitworth J; Andrews KA; Roberts T; Clark GR; West H; Smith PS; Docquier FM; Rodger F; Murray V; Simpson HL; Wallis Y; Giger O; Tran M; Tomkins S; Stewart GD; Park SM; Woodward ER; Maher ER
J Clin Endocrinol Metab; 2017 Nov; 102(11):4013-4022. PubMed ID: 28973655
[TBL] [Abstract][Full Text] [Related]
23. Genotype-phenotype correlation in paediatric pheochromocytoma and paraganglioma: a single centre experience from India.
Khadilkar K; Sarathi V; Kasaliwal R; Pandit R; Goroshi M; Shivane V; Lila A; Bandgar T; Shah NS
J Pediatr Endocrinol Metab; 2017 May; 30(5):575-581. PubMed ID: 28432847
[TBL] [Abstract][Full Text] [Related]
24. Familial nonsyndromic pheochromocytoma.
Opocher G; Schiavi F; Iacobone M; Toniato A; Sattarova S; Erlic Z; Martella M; Mian C; Merante Boschin I; Zambonin L; De Lazzari P; Murgia A; Pelizzo MR; Favia G; Mantero F
Ann N Y Acad Sci; 2006 Aug; 1073():149-55. PubMed ID: 17102081
[TBL] [Abstract][Full Text] [Related]
25. Mutations seen among patients with pheochromocytoma and paraganglioma at a referral center from India.
Pai R; Ebenazer A; Paul MJ; Thomas N; Nair A; Seshadri MS; Oommen R; Shanthly N; Devasia A; Rebekah G; Jeyaseelan L; Rajaratnam S
Horm Metab Res; 2015 Feb; 47(2):133-7. PubMed ID: 24977658
[TBL] [Abstract][Full Text] [Related]
26. Role of miR-101 in pheochromocytoma patients with SDHD mutation.
Zong L; Meng L; Shi R
Int J Clin Exp Pathol; 2015; 8(2):1545-54. PubMed ID: 25973039
[TBL] [Abstract][Full Text] [Related]
27. Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma.
Meyer-Rochow GY; Smith JM; Richardson AL; Marsh DJ; Sidhu SB; Robinson BG; Benn DE
J Surg Res; 2009 Nov; 157(1):55-62. PubMed ID: 19215943
[TBL] [Abstract][Full Text] [Related]
28. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
Bausch B; Schiavi F; Ni Y; Welander J; Patocs A; Ngeow J; Wellner U; Malinoc A; Taschin E; Barbon G; Lanza V; Söderkvist P; Stenman A; Larsson C; Svahn F; Chen JL; Marquard J; Fraenkel M; Walter MA; Peczkowska M; Prejbisz A; Jarzab B; Hasse-Lazar K; Petersenn S; Moeller LC; Meyer A; Reisch N; Trupka A; Brase C; Galiano M; Preuss SF; Kwok P; Lendvai N; Berisha G; Makay Ö; Boedeker CC; Weryha G; Racz K; Januszewicz A; Walz MK; Gimm O; Opocher G; Eng C; Neumann HPH;
JAMA Oncol; 2017 Sep; 3(9):1204-1212. PubMed ID: 28384794
[TBL] [Abstract][Full Text] [Related]
29. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
[TBL] [Abstract][Full Text] [Related]
30. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing.
Fishbein L; Merrill S; Fraker DL; Cohen DL; Nathanson KL
Ann Surg Oncol; 2013 May; 20(5):1444-50. PubMed ID: 23512077
[TBL] [Abstract][Full Text] [Related]
31. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma.
Meyer-Rochow GY; Schembri GP; Benn DE; Sywak MS; Delbridge LW; Robinson BG; Roach PJ; Sidhu SB
Ann Surg Oncol; 2010 Feb; 17(2):392-400. PubMed ID: 19949879
[TBL] [Abstract][Full Text] [Related]
32. Multimodality Radionuclide Imaging in a Patient With Hereditary Paraganglioma-Pheochromocytoma Syndrome.
Yim SY; Moncayo VM; Pasquel FJ; Halkar RK
Clin Nucl Med; 2017 Dec; 42(12):964-965. PubMed ID: 28902732
[TBL] [Abstract][Full Text] [Related]
33. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
Ricketts CJ; Forman JR; Rattenberry E; Bradshaw N; Lalloo F; Izatt L; Cole TR; Armstrong R; Kumar VK; Morrison PJ; Atkinson AB; Douglas F; Ball SG; Cook J; Srirangalingam U; Killick P; Kirby G; Aylwin S; Woodward ER; Evans DG; Hodgson SV; Murday V; Chew SL; Connell JM; Blundell TL; Macdonald F; Maher ER
Hum Mutat; 2010 Jan; 31(1):41-51. PubMed ID: 19802898
[TBL] [Abstract][Full Text] [Related]
34. A case of (123)I-MIBG scintigram-negative functioning pheochromocytoma: immunohistochemical and molecular analysis with review of literature.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Yao T
Int J Clin Exp Pathol; 2014; 7(7):4438-47. PubMed ID: 25120831
[TBL] [Abstract][Full Text] [Related]
35. Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.
Buffet A; Ben Aim L; Leboulleux S; Drui D; Vezzosi D; Libé R; Ajzenberg C; Bernardeschi D; Cariou B; Chabolle F; Chabre O; Darrouzet V; Delemer B; Desailloud R; Goichot B; Esvant A; Offredo L; Herman P; Laboureau S; Lefebvre H; Pierre P; Raingeard I; Reznik Y; Sadoul JL; Hadoux J; Tabarin A; Tauveron I; Zenaty D; Favier J; Bertherat J; Baudin E; Amar L; Gimenez-Roqueplo AP;
J Clin Endocrinol Metab; 2019 Apr; 104(4):1109-1118. PubMed ID: 30698717
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Factors of Malignant Pheochromocytoma and Paraganglioma: A Combined SEER and TCGA Databases Review.
Mei L; Khurana A; Al-Juhaishi T; Faber A; Celi F; Smith S; Boikos S
Horm Metab Res; 2019 Jul; 51(7):451-457. PubMed ID: 30919391
[TBL] [Abstract][Full Text] [Related]
37. Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.
Namba H; Kondo H; Yamashita S; Kimura H; Yokoyama N; Tsuruta M; Sato A; Izumi M; Kinoshita H; Hakariya S
Ann Nucl Med; 1992 May; 6(2):111-5. PubMed ID: 1352456
[TBL] [Abstract][Full Text] [Related]
38. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
Hoefnagel CA; Schornagel J; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):308-12. PubMed ID: 1823843
[TBL] [Abstract][Full Text] [Related]
39. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.
Erlic Z; Rybicki L; Peczkowska M; Golcher H; Kann PH; Brauckhoff M; Müssig K; Muresan M; Schäffler A; Reisch N; Schott M; Fassnacht M; Opocher G; Klose S; Fottner C; Forrer F; Plöckinger U; Petersenn S; Zabolotny D; Kollukch O; Yaremchuk S; Januszewicz A; Walz MK; Eng C; Neumann HP;
Clin Cancer Res; 2009 Oct; 15(20):6378-85. PubMed ID: 19825962
[TBL] [Abstract][Full Text] [Related]
40. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
